Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Wellman
Brigham and Women's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Apnimed Corp.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The research investigates phenotype categorization and treatments for sleep apnea, particularly pharmacologic treatments that may affect pharyngeal muscle activity during sleep. Dr. Wellman owns equity in Apnimed, a company developing drug therapies for obstructive sleep apnea. Given the investigator’s private equity interest, it was determined that the interest could affect the design, conduct, or reporting of the research projects, resulting in a financial conflict of interest under the PHS regulations.
Phenotypic and Molecular Signatures for Sleep Apnea and Related Morbidities
Sleep apnea is a common disorder associated with many adverse health outcomes, but often unrecognized and under-treated. The usual measure of disease severity, the Apnea Hypopnea Index, does not adequately characterize disease subtypes reflective of differences in underlying anatomic and physiological risk factors, and thus poorly predicts which patients are most susceptible to adverse health outcomes and would benefit from treatment. The mainstay treatment is a CPAP machine, which stents the airway open without treating the underlying cause of the apnea. This program will systematically identify new measures of sleep apnea that reflect underlying mechanisms and allow subgroups of patients to be better characterized, facilitating the discovery of the molecular basis for sleep apnea and novel treatments.
Filed on March 15, 2018.
Tell us what you know about David Wellman's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “David Wellman”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Wellman | Brigham and Women's Hospital | Conflict of Interest | Apnimed Corp. | Value cannot be readily determined |
| David Wellman | Brigham and Women's Hospital | Conflict of Interest | Apnimed Corp. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.